WO2017185766A1 - Procédé de conception d'amorces et de sonde pour l'amplification d'une séquence cible mutante à faible concentration - Google Patents

Procédé de conception d'amorces et de sonde pour l'amplification d'une séquence cible mutante à faible concentration Download PDF

Info

Publication number
WO2017185766A1
WO2017185766A1 PCT/CN2016/109623 CN2016109623W WO2017185766A1 WO 2017185766 A1 WO2017185766 A1 WO 2017185766A1 CN 2016109623 W CN2016109623 W CN 2016109623W WO 2017185766 A1 WO2017185766 A1 WO 2017185766A1
Authority
WO
WIPO (PCT)
Prior art keywords
primer
amplification
primers
base
mutant
Prior art date
Application number
PCT/CN2016/109623
Other languages
English (en)
Chinese (zh)
Inventor
邹鸿志
牛智通
Original Assignee
广州市康立明生物科技有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广州市康立明生物科技有限责任公司 filed Critical 广州市康立明生物科技有限责任公司
Publication of WO2017185766A1 publication Critical patent/WO2017185766A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification

Definitions

  • the invention belongs to the technical field of molecular biology and relates to a novel method for designing nucleic acid primers and probes. More specifically, it relates to a method of designing primers and probes for amplifying low concentration mutant target sequences.
  • PCR PolymeraseChainReaction
  • PCR PolymeraseChainReaction
  • parental DNA DNA as a template
  • specific primers as an extension starting point
  • replicating and parenting the template in vitro by denaturation, annealing and extension.
  • the process of DNA complementary daughter strand DNA is a DNA in vitro synthesis amplification technology that can rapidly and specifically amplify any DNA of interest in vitro. It can be used for gene isolation and cloning, sequence analysis, gene expression regulation, gene polymorphism research and many other aspects.
  • the double-stranded DNA can be degenerated into a single strand under the action of various enzymes, and is replicated into the same two copies according to the principle of base complementary pairing with the participation of DNA polymerase and promoter.
  • DNA can also undergo denaturing and melting at high temperatures, and when the temperature is lowered, it can be renatured into a double strand. Therefore, by controlling the denaturation and renaturation of DNA by temperature changes, and designing primers as promoters, DNA polymerase and dNTP can be added to complete the in vitro replication of specific genes.
  • PCR is similar to the natural replication process of DNA, and its specificity depends on oligonucleotide primers complementary to both ends of the target sequence.
  • PCR consists of three basic reaction steps of denaturation-annealing (refolding)-extension: 1 denaturation of template DNA: template DNA is heated to 94 ° C After a certain period of time, the double-stranded DNA of the template DNA double-stranded or amplified by PCR is dissociated to make it a single strand, so that it binds to the primer to prepare for the next round reaction; 2 annealing of the template DNA and the primer ( Refolding): After the template DNA is denatured into a single strand by heating, the temperature is lowered to about 40-60 ° C, and the primers are paired with the complementary sequence of the single strand of the template DNA; 3 primer extension: DNA template-primer conjugate in the DNA polymerase Under the action of 72 °C, dNTP as the reaction material, the target sequence as a template, according to the principle of base pairing and semi-reserved replication, synthesize a new semi-reserved replication strand complementary to the template DNA
  • PCR technology is often used in clinical medicine, such as detection of hepatitis B virus, tumors, pathogens, and the like. Many common tumor diseases in humans are closely related to the genetic causes of certain viral diseases and tumor-related genes. PCR technology has achieved gratifying results in the research of tumor virus etiology, tumor-related genes, tumor-associated tumor suppressor genes. It is also used for genetic diseases with multiple point mutations. PCR is applied to paternity testing, blood group identification, and fingerprint identification in law. For blood samples that cannot be traced by traditional serological methods, the ABO and MN blood types can be tested by PCR. The verification of biological materials at certain crime sites will provide forensic medicine with reliable and effective evidence and direct and efficient data.
  • primers and probes are a critical prerequisite.
  • the shortcomings of existing PCR techniques are mainly reflected in the design of primers and probes. Poor sex, primers and probes designed according to common methods for gene mutations often produce non-specific amplification bands; 2 poor selectivity, in the context of higher wild-type templates, for lower levels of genes Mutant DNA has limited detection ability, and most of the mutations that cause tumors are somatic mutations.
  • Mutant cells are doped in wild-type cells, so the proposed DNA also carries a large amount of wild-type DNA; In the case of a small sample size or complex background interference in the sample, it is difficult to produce effective DNA amplification using the extracted DNA, or even cause detection or false negatives.
  • the technical problem to be solved by the present invention is to overcome the defects and shortcomings of the existing gene mutation detection primers and probe design methods, and to provide a design method for amplifying primers and probes for low-content mutant DNA in the background of high content of wild-type DNA. And its application in the field of nucleic acid detection.
  • the primers and probes designed according to the method of the present invention can efficiently amplify a target fragment in the background of a higher wild-type template, and are a simple, inexpensive, highly efficient and highly specific PCR amplification primer for amplifying a target fragment. And probe design methods.
  • the present invention provides the following technical solutions:
  • the present invention provides a method of obtaining primers and/or probes comprising the steps of:
  • the number of bases of the mutation point on the target sequence to be amplified is 0, the 5' direction of the base of the mutation is negative, the 3' direction is positive, and the base from the point of mutation to the 5' direction
  • the number of bits is called -1, -2, -3... in turn;
  • the number of bases from the point of mutation to the 3' direction is called +1, +2, +3... in turn;
  • a 15-25 bp nucleic acid fragment containing 0 bases is selected as the forward primer for amplification; the -1 to -4 position of the forward primer can be introduced according to the needs of the assay. Base or multi-base mismatch to adjust the specificity of amplification and the efficiency of amplification;
  • a 12-25 bp nucleic acid sequence is selected from the -1 base or the 0 base as a probe sequence of the amplification system;
  • the reverse primer is designed according to a conventional primer design method.
  • the effect of the introduction of the mismatched base pair on the amplification specificity of the forward primer in the step S3 of the method is: -1 position > -2 position > -3 position > -4 Position; that is, the amplification specificity of introducing a mismatch base at position -1 is the highest.
  • the 5' end of the probe sequence of the method step S4 is labeled with a fluorophore and the 3' end is labeled with a corresponding quencher.
  • the base at position -1 on the probe sequence of the method step S4 may be the same as that on the primer, or may be different from the primer.
  • the method step S3 is negative at the point of mutation In the direction, a nucleic acid fragment of 18 to 23 bp including the base 0 is selected as an amplified forward primer.
  • the method step S4 is to select a 15-23 bp nucleic acid sequence from the -1 base or the 0 base as the probe sequence of the amplification system in the positive direction of the mutation point.
  • the invention also provides primers and/or probes obtained by the methods described.
  • the invention also provides the use of the primers and/or probes described in amplifying a low concentration mutant target sequence.
  • the amplifying the low concentration mutant target sequence is specifically for amplifying a low concentration mutant DNA.
  • the invention also provides the use of the primers and/or probes to amplify low levels of mutated DNA in the context of high levels of wild-type DNA.
  • the invention also provides the use of the primers and/or probes described for detecting genetic mutations and/or single nucleotide polymorphisms.
  • the invention also provides a method for PCR amplification using the primers and/or probes, which comprises the following steps:
  • the present invention discloses a method for designing primers and probes for amplifying low concentration mutant target sequences. First, determine the position of the mutation (mutation point, ie, position 0) of the target sequence to be amplified; then, select the 15-25 bp nucleic acid fragment containing the 0 base as the forward primer in the negative direction of the mutation point, at the mutation point.
  • the 12-25 bp nucleic acid sequence is selected as the probe sequence of the amplification system from the base of the -1 base or the base of the base; and finally, the reverse primer is designed according to a conventional method at a suitable position downstream of the probe sequence in the 3' direction.
  • Primers and probes designed according to the method of the present invention can efficiently (high specificity and high efficiency) amplify a fragment of interest in the context of a higher content of wild-type template, especially for point mutations, deletion mutations, and Insertion mutations, combined with fluorescence real-time PCR technology, can be very effective in solving the current difficulties in the sensitivity of tumor detection and drug sensitivity detection.
  • Figure 1 is a schematic diagram of PCR amplification reaction of primers and probes designed according to the present invention; including Figure a and Figure b;
  • Figure 2 is a diagram showing the amplification of the G G T>G C T mutant and the wild type of the primers and probes designed according to the method of the present invention in Example 1 on the codon 12 of the Kras gene;
  • Figure 3 is a diagram showing the amplification of the G G T>G C T mutant and the wild type of the primers and probes designed according to the conventional method in Example 1 on the codon 12 of the Kras gene;
  • Figure 4 is a diagram showing the amplification of the BRAF gene V600E mutant and wild type by primers and probes according to the method of the present invention in Example 2;
  • Figure 5 is a diagram showing the amplification of the BRAF gene V600E mutant and wild type by primers and probes according to the conventional method in Example 2;
  • Figure 6 is a diagram showing the amplification of PIK3CA gene c.3140A>G mutant and wild type by primers and probes designed in the method of the present invention in Example 3;
  • Figure 7 is a diagram showing the amplification of the PIK3CA gene c.3140A>G mutant and the wild type using the primers and probes designed in the ordinary method in Example 3;
  • Figure 8 is an amplification of the (c.2311T2C; p.L771L) mutant and wild type of the BRCA1 gene using primers and probes designed using the method of the present invention
  • Figure 9 is a diagram showing amplification of BRCA1 gene c.2311T2C; p.L771L mutant and wild type using primers and probes designed by a common method;
  • Figure 10 is a diagram showing the amplification of c.2573T2G; p. L858R mutant and wild type of EGFR gene using primers and probes designed by the method of the present invention;
  • Figure 11 shows the amplification of c.2573T2G; p.L858R mutant and wild type of EGFR gene using primers and probes designed by common methods;
  • Figure 12 is a diagram showing the amplification of c.182A>G; p.Q61R mutant and wild type of NRAS gene using primers and probes designed by the method described in the present patent;
  • Figure 13 is a diagram showing the amplification of c.182A>G; p.Q61R mutant and wild type of NRAS gene using primers and probes designed by a common method;
  • Figure 14 is a diagram showing the amplification of c.524G>A; p.R175H mutant and wild type of TP53 gene using primers and probes designed by the method described in the present patent;
  • Figure 15 is a diagram showing the amplification of c.524G>A; p.R175H mutant and wild type of TP53 gene by primers and probes designed by a common method;
  • Figure 16 is a representation of the amplification of the RET gene c.2753T>C; p.M918T mutant and wild type using primers and probes designed using the methods described in the present patent;
  • Figure 17 shows the amplification of the RET gene c.2753T>C; p.M918T mutant and wild type using primers and probes designed by the conventional method.
  • the invention discloses a design method for a primer and a probe for amplifying a low concentration mutant target sequence, and those skilled in the art can learn from the contents of the present article and appropriately improve the process parameters. It is to be understood that all such alternatives and modifications are obvious to those skilled in the art and are considered to be included in the present invention.
  • the method and the application of the present invention have been described by the preferred embodiments, and it is obvious that the method and application described herein may be modified or appropriately modified and combined without departing from the scope of the present invention. The technique of the present invention is applied.
  • Another object of the present invention is to provide a method for designing primers and probes for amplifying a low concentration of a mutant target sequence.
  • Still another object of the present invention is to provide an application of the above-described primer and probe design method.
  • a method for designing primers and probes for amplifying a low concentration mutant target sequence preferably, the primers and probes for amplifying a low concentration mutant target sequence are specifically for amplifying a low concentration mutant DNA.
  • Primers and probes (lower mutated DNA amplified in the context of high wild-type DNA).
  • the design method includes the following steps:
  • the definition is as follows: the number of bits of the base of the mutation point on the target sequence to be amplified is 0, and the 5' direction of the base of the mutation is negative, 3' The direction is positive, and the number of bases from the point of mutation to the 5' direction is called -1, -2, -3, respectively; the number of bases from the point of mutation to the 3' direction is called +1. , +2, +3... bits;
  • a 15-25 bp nucleic acid fragment containing 0 bases is selected as the forward primer for amplification; the -1 to -4 position of the forward primer can be introduced according to the needs of the assay. Base or multi-base mismatch to adjust the specificity of amplification and the efficiency of amplification;
  • a 12-25 bp nucleic acid sequence is selected from the -1 base or the 0 base as a probe sequence of the amplification system; since the sequence of the probe is from -1 or 0 Initially, therefore, the method of the present invention has an obvious feature in structure: the 3' end of the forward primer and the 5' end of the probe have an overlap of 1 bp or 2 bp;
  • the reverse primer is designed in a conventional manner downstream of the probe sequence in the 3' direction.
  • the effect of the introduction of the mismatched base pair on the amplification specificity of the forward primer in the step S3 is: -1 bit > -2 position > -3 position > -4 position;
  • the base has the highest amplification specificity.
  • the probe sequence of step S4 is labeled with a fluorophore at the 5' end and a corresponding quencher group at the 3' end.
  • the labeling group can be a conventional labeling group such as FAM, VIC, HEX, and the corresponding quenching group.
  • the labeled fluorophore and quenching group are FAM and BHQ1.
  • the sequence of the probe should be designed to be as short as possible.
  • the base at position -1 on the probe sequence in step S4 may be the same as on the primer or different from the primer.
  • the GC content of the designed primer and probe is preferably between 40% and 60%.
  • the forward primer can be obtained by appropriately adjusting the length of the primer and the type of the introduced mismatch base and the introduction of a suitable length of the unrelated sequence at the 5' end; the probe sequence can be adjusted by adjusting the length of the probe, and marking different The fluorophore either introduces an unrelated sequence at the 3' end, but the overall design requirements of the probe are preferably short and not too long.
  • a nucleic acid fragment of 18 to 23 bp including the base 0 is selected as the amplified forward primer.
  • step S4 is a probe sequence of an amplification system in which a 15- to 23 bp nucleic acid sequence is selected from the -1 base or the 0 base in the positive direction of the mutation point.
  • PCR amplification using the primers and probes designed by the present invention includes the following steps:
  • the number of cycles in the second step is set to 3 to 10 cycles, and the annealing temperature is set to 56 ° C to 65 ° C.
  • the results show that the annealing temperature is set to 56 ° C to 65 ° C at this temperature.
  • the primers that are most favorable for design and the target sequence template specifically bind, and the primers are designed to bind to the wild-type template with the lowest possibility, so that the mutant template in the high-content wild-type background can be amplified in a large amount, which is beneficial to the subsequent
  • the third part of the cycle and the amplification efficiency of the entire system is set to 3 to 10 cycles, and the annealing temperature is set to 56 ° C to 65 ° C.
  • the number of PCR amplification cycles in the third step is set to 30 to 45, preferably 35, which may be determined as needed, and the annealing temperature of the portion is 5 to 8 ° C lower than the annealing temperature of the first portion.
  • the ratio of the mutant template to the wild type template in this part has been significantly higher than that in the initial sample, so lowering the annealing temperature is more effective for the mutant target.
  • Amplification of the sequence After amplification of the second part, a small number of mutations are enriched millions of times, while the wild-type template is completely at a disadvantage of binding and fluorescence during the entire amplification process, with almost no amplification. In this way, a very small amount of mutant DNA in the DNA template to be detected can be detected well. Studies have shown that this method can be used to design primers and probes to effectively detect 0.1% or more mutations.
  • the components of DNA polymerase, dNTP, Mg 2+ and system buffer in the reaction solution are the same as ordinary PCR, and can be optimized according to different reactions. .
  • primers and probes for detecting genetic mutations and/or single nucleotide polymorphisms are also within the scope of the present invention.
  • Primers and/or probes designed according to this method are well suited for detecting genetic mutations, single nucleotide polymorphisms, and/or SNPs.
  • Primer design was performed according to the conventional design method with the mutated strand as the target sequence strand, and the mutation point was placed at the 3' end of the primer; due to the matching at the 3' end It is critical for amplification, so the amplification efficiency of this primer is extremely low for unmatched wild-type templates, which is the first heavy amplification specific enhancement. Then, a number of mismatched bases are artificially introduced on the primers, and the new strand amplified after the mismatched base is introduced will completely match the primers, and the original wild-type strand or the mutant strand does not match the primer. Perfect match, but the mutant strand is easier to match with the primer than the wild type strand. Setting the higher annealing temperature in the first stage is to ensure that the primer and the wild type template are combined as much as possible during the amplification process. Specific amplification provides a second guarantee for enrichment of low abundance mutant templates in the first few cycles.
  • Probe design The probe design in this method is basically a sequence of 15-22 bp downstream from -1 or -2, and the probe length can be adjusted according to actual test conditions. Since the 0th position is the mutation point and the probe also contains the mutated base at position 0, adjusting the appropriate annealing temperature according to the Tm value of the probe allows the probe to preferentially bind to the target sequence instead of the wild type sequence. To increase the specificity of the role.
  • FIG. 1 A schematic diagram of a PCR amplification reaction of primers and probes designed in accordance with the present invention is shown in FIG.
  • the process of amplification is explained as follows: at the denaturation temperature, the double strands of the DNA are unfolded to form a single strand, respectively; during the initial annealing phase, the DNA strand is renatured, and the primer binds to the DNA template strand. Since the annealing temperature of the first stage is higher, for the mutant template, the end of the primer and the mutation point on the template are matched, so it is easier to bind to the mutant template strand; while the wild type template is not because of the end.
  • the most important feature of the primers and probes designed by the present invention is that the 3' end of the primer and the 5' end of the probe have an overlap of 1 to 2 bp. This amplification is not only primer specific but also probe specific. This double restriction further ensures the specificity and efficiency of amplification.
  • the forward primer designed by the present invention can introduce an appropriate mismatch base according to the result of amplification and the need to increase the specificity of amplification or increase the efficiency of amplification, and ensure amplification specificity.
  • the corresponding Ct value can be optimized according to the introduced mismatch, which is beneficial to the optimization of the process in the multiplex PCR system.
  • the labeling group of the probe sequence designed by the method may select a conventional labeling group such as FAM, VIC, HEX or the like and a corresponding quenching group, and more preferably the labeled fluorophore and quenching group are FAM and BHQ1. .
  • the sequence of the probe should be designed to be as short as possible.
  • the primer and probe design methods of the present invention are directed to point mutations, deletion mutations, and insertion mutations in gene mutations, and combined with real-time PCR technology can effectively solve the current lack of sensitivity in clinical detection and drug sensitivity detection. Difficulties.
  • the materials and reagents used in the design method of the primers and probes for amplifying a low concentration mutant target sequence provided by the present invention are commercially available.
  • primers and probe sequences designed in accordance with the methods of the invention are as follows:
  • SEQ ID No. 1 Kras-0Fp: CACTCTTGCCTACGCCTG;
  • SEQ ID No. 2 Kras-0Pb: TGCAGCTCCAACTACCAC;
  • SEQ ID No. 3 Kras-0Rp: GGCCTGCTGAAAATGACTG.
  • primers and probes designed according to the general conventional primer and probe design methods are as follows:
  • SEQ ID No. 4 Kras-1 Fp: CACTCTTGCCTACGCCTG;
  • SEQ ID No. 5 Kras-1Pb: GCTCCAACTACCACAAGTT;
  • SEQ ID No. 6 Kras-1Rp: GGCCTGCTGAAAATGACTG.
  • a sequence carrying the G G T>G C T mutation and the corresponding Kras wild sequence were artificially synthesized, and the two sequences were separately loaded into a plasmid for amplification.
  • the synthesized plasmid was digested and a fragment of 10 4 copies of the fragment was obtained, and then the two were mixed in different ratios to obtain samples containing different concentrations of mutant and wild type: 100% mutant, 50% mutant, 10% mutant, 5% mutant, 1% mutant, 0.1% mutant and 100% wild type sample template.
  • the first part of the 10 cycles 95 ° C 20s, 62 ° C 30s, 72 ° C 20s;
  • the second part of the 40 cycles 95 ° C for 20 s, 58 ° C for 30 s, 72 ° C for 20 s and collect fluorescent signals.
  • Figure 2 shows the amplification effect of primers and probes designed according to the method of the present invention. The results show that the wild type template is very low in amplification and can effectively distinguish 0.1% of the mutation types.
  • Figure 3 shows the amplification effect of primers and probes designed according to the conventional method.
  • the wild type template amplification is more obvious, and only 1% of the mutation types can be distinguished.
  • the comparison between the two is shown in Table 2.
  • SEQ ID No. 7 BRAF-0Fp: CCCACTCCATCGAGATGTCT;
  • SEQ ID No. 8 BRAF-0Rp: TGAAGACCTCACAGTAAAA;
  • SEQ ID No. 10 BRAF-1Fp: CCCACTCCATCGAGATTTCT;
  • SEQ ID No. 11 BRAF-1Rp: TGAAGACCCTCACAGTAAAA;
  • SEQ ID No. 12 BRAF-1 Pb: CTGTAGCTAGACCAA.
  • a sequence with the BRAFV600E mutation and the corresponding BRAF wild sequence were artificially synthesized, and the two sequences were separately loaded into a plasmid for amplification.
  • the synthesized plasmid was digested with a restriction enzyme system to obtain a 10 4 copy number fragment, and then mixed in different ratios to obtain samples containing different concentrations of mutant and wild type: 100% mutant. 50% mutant, 10% mutant, 5% mutant, 1% mutant, 0.1% mutant and 100% wild type sample template.
  • the first part of the 10 cycles 95 ° C 20s, 62 ° C 30s, 72 ° C 20s;
  • the second part of 40 cycles 95 ° C for 20 s, 55 ° C for 30 s, 72 ° C for 20 s and collect fluorescent signals.
  • Figure 4 is a graph showing the effect of primer and probe design on the detection of BRAFV600E mutations in accordance with the methods of the present invention.
  • Figure 5 shows the design of primers and probes for BRAFV600E mutation according to the conventional method. Detect the effect.
  • SEQ ID No. 13 PIK-0Fp: AACAAATGAATGATGCGCG
  • SEQ ID No. 16 PIK-1Fp: CAAATGAATGATGCACG
  • SEQ ID No. 18 PIK-1Pb: ATGGTGGCTGGACAACA
  • a sequence carrying the PIK3CAc.3140A>G mutation and the corresponding PIK3CA wild sequence were artificially synthesized, and the two sequences were separately loaded into a plasmid for amplification.
  • the synthesized plasmid was digested with a restriction enzyme system to obtain a digested fragment of 10 4 copies, and then mixed in different ratios to obtain samples containing different concentrations of mutant and wild type: 100% mutant, 50 % mutant, 10% mutant, 5% mutant, 1% mutant, 0.1% mutant and 100% wild type sample template.
  • the first part of the 10 cycles 95 ° C 20s, 62 ° C 30s, 72 ° C 20s;
  • the second part of 40 cycles 95 ° C for 20 s, 55 ° C for 30 s, 72 ° C for 20 s and collect fluorescent signals.
  • Figure 6 is a primer and probe pair designed using the method of the present invention to PIK3CAc.3140A>G Amplification of genes.
  • Figure 7 shows the amplification of the PIK3CAc.3140A>G gene using primers and probes designed using conventional methods.
  • SEQ ID No. 21 BRC-0Pb: GTGAAATACTGCTACTCTC
  • SEQ ID No. 22 BRC-1Fp: AATCAGTACCAGGTAGCAG
  • SEQ ID No. 24 BRC-1Pb: GAAATACTGCTACTCTCTAC
  • a sequence carrying the BRCA1 gene (c.2311T2C; p.L771L) SNP site and the corresponding BRCA1 wild sequence were artificially synthesized and loaded into a plasmid for amplification.
  • the synthesized plasmid was digested with a restriction enzyme system and a fragment of 10 4 copies of the fragment was obtained as a template for fluorescent PCR amplification.
  • the real-time PCR reaction procedure was: 95 ° C for 5 min; 50 cycles: 95 ° C for 20 s, 51 ° C for 30 s, 72 ° C for 30 s and collect fluorescent signals.
  • SEQ ID No. 25 EGFR-0Fp: CAAGATCACAGATTTTGCGCG
  • SEQ ID No. 26 EGFR-0Rp: CTTACTTTGCCTCCTTCTGC
  • SEQ ID No. 27 EGFR-0Pb: GGCCCAAACTGCTGGGT
  • SEQ ID No. 28 EGFR-1 Fp: CAAGATCACAGATTTTGCGCG
  • SEQ ID No. 29 EGFR-1Rp: CTTACTTTGCCTCCTTCTGC
  • SEQ ID No. 30 EGFR-1 Pb: GCCAAACTGCTGGGTGCGGA
  • a sequence carrying the EGFR gene c.2573T2G; p. L858R mutation site and the corresponding EGFR wild sequence were artificially synthesized and loaded into a plasmid for amplification.
  • the synthesized plasmid was digested with a restriction enzyme system and a fragment of 10 4 copies of the fragment was obtained as a template for fluorescent PCR amplification.
  • the real-time PCR reaction procedure was: 95 ° C for 5 min; 50 cycles: 95 ° C for 20 s, 48 ° C for 30 s, 72 ° C for 30 s and collect fluorescent signals.
  • the primers and probes designed by the method of the present invention and the primers and probes designed according to the conventional method were respectively used to detect the c.182A>G; p.Q61R mutant of the NRAS gene and compare the effects.
  • SEQ ID No. 31 NRAS-0Fp: CATGGCACTGTACTCTGCTC
  • SEQ ID No. 32 NRAS-0Rp: ACCCCCAGGATTCTTACAGA
  • SEQ ID No. 33 NRAS-0Pb: CGTCCAGCTGTATCCAGTATG
  • SEQ ID No. 34 NRAS-1Fp: CATGGCACTGTACTCTGCTC
  • SEQ ID No. 35 NRAS-1Rp: ACCCCCAGGATTCTTACAGA
  • SEQ ID No. 36 NRAS-1 Pb: CCAGCTGTATCCAGTATGTCC
  • a sequence carrying the NRAS gene c.182A>G; p.Q61R mutation site and the corresponding NRAS wild sequence were artificially synthesized and loaded into a plasmid for amplification.
  • the synthesized plasmid was digested with a restriction enzyme system and a fragment of 10 4 copies of the fragment was obtained as a template for fluorescent PCR amplification.
  • the real-time PCR reaction procedure was: 95 ° C for 5 min; 50 cycles: 95 ° C for 20 s, 48 ° C for 30 s, 72 ° C for 30 s and collect fluorescent signals.
  • the primers and probes designed by the method described in the present invention and the primers and probes designed according to the conventional method were respectively used to detect the c.524G>A; p.R175H mutant of the TP53 gene, and the effects were compared.
  • SEQ ID No. 38 TP53-0Rp: TTGATTCCACACCCCCGCC
  • SEQ ID No. 42 TP53-1Pb: ACAACCTCCGTCATGTGCTG
  • a sequence carrying the TP53 gene c.524G>A; p.R175H mutation site and the corresponding TP53 wild sequence were artificially synthesized and loaded into a plasmid for amplification.
  • the synthesized plasmid was digested with a restriction enzyme system and a fragment of 10 4 copies of the fragment was obtained as a template for fluorescent PCR amplification.
  • the real-time PCR reaction procedure was: 95 ° C for 5 min; 50 cycles: 95 ° C for 20 s, 48 ° C for 30 s, 72 ° C for 30 s and collect fluorescent signals.
  • the primers and probes designed by the method of the present invention are designed and the primers and probes are designed according to an ordinary method, and the c.2753T>C; p. M918T mutant of the RET gene is separately detected and compared.
  • SEQ ID No. 43 RET-0Fp: CGGATTCCAGTTAAATCGAC
  • SEQ ID No. 46 RET-1Fp: CGGATTCCAGTTAAATCGAC
  • SEQ ID No. 48 RET-1 Pb: GCAATTGAATCCCTTCTTG
  • a sequence carrying the RET gene c.2753T>C; p.M918T mutation site and the corresponding RET wild sequence were artificially synthesized, and the two sequences were separately loaded into a plasmid for amplification.
  • the synthesized plasmid was digested with a restriction enzyme system and a fragment of 10 4 copies of the fragment was obtained as a template for fluorescent PCR amplification.
  • the real-time PCR reaction procedure was: 95 ° C for 5 min; 50 cycles: 95 ° C for 20 s, 48 ° C for 30 s, 72 ° C for 30 s and collect fluorescent signals.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de conception d'amorces et d'une sonde pour l'amplification d'une séquence cible mutante à faible concentration qui comprend : premièrement, la détermination d'une position mutante d'une séquence cible à amplifier, la sélection d'un fragment d'acide nucléique de 12 à 25 pb comprenant une base au niveau du site 0 dans une direction négative du site mutant pour servir d'amorce sens, et la sélection d'une séquence d'acide nucléique de 12 à 25 pb à partir d'une base au niveau du site -1 ou de la base au niveau du site 0 dans une direction positive du site mutant pour servir de séquence de sonde du système d'amplification ; et enfin la conception d'une amorce antisens à une position aval appropriée d'une direction 3' de la séquence de sonde au moyen d'un procédé classique.
PCT/CN2016/109623 2016-04-29 2016-12-13 Procédé de conception d'amorces et de sonde pour l'amplification d'une séquence cible mutante à faible concentration WO2017185766A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610281016.3A CN105861678B (zh) 2016-04-29 2016-04-29 一种用于扩增低浓度突变靶序列的引物和探针的设计方法
CN201610281016.3 2016-04-29

Publications (1)

Publication Number Publication Date
WO2017185766A1 true WO2017185766A1 (fr) 2017-11-02

Family

ID=56630019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/109623 WO2017185766A1 (fr) 2016-04-29 2016-12-13 Procédé de conception d'amorces et de sonde pour l'amplification d'une séquence cible mutante à faible concentration

Country Status (2)

Country Link
CN (2) CN105861678B (fr)
WO (1) WO2017185766A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110551815A (zh) * 2018-05-30 2019-12-10 苏州云泰生物医药科技有限公司 检测人Ras基因突变的试剂盒及其使用方法
CN112481382A (zh) * 2020-12-09 2021-03-12 凯杰生物工程（深圳）有限公司 一种用于检测jak2基因的引物组合物和探针、试剂盒以及方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105861678B (zh) * 2016-04-29 2019-12-13 广州市康立明生物科技有限责任公司 一种用于扩增低浓度突变靶序列的引物和探针的设计方法
CN108624662A (zh) * 2017-03-23 2018-10-09 陈汉奎 稀有基因突变的检测
CN108300785A (zh) * 2018-02-13 2018-07-20 无锡禾盛医疗器械有限公司 一种braf基因突变检测的引物探针组合及其应用
CN111378751A (zh) * 2018-12-29 2020-07-07 成都华青精准医疗科技有限公司 一种用于检测kras基因突变的核苷酸序列组及其应用
CN109666747A (zh) * 2019-02-20 2019-04-23 天津脉络医学检验有限公司 一种引物探针组合物及其应用
CN109762906B (zh) * 2019-03-26 2023-07-14 上海桐树生物科技有限公司 一种用于肿瘤基因变异检测的方法、引物、探针和检测剂
CN113234794A (zh) * 2021-06-08 2021-08-10 重庆中元汇吉生物技术有限公司 一种提升pcr扩增效率的引物探针设计方法
CN116130000B (zh) * 2022-12-02 2023-12-12 武汉艾米森生命科技有限公司 引物探针序列组合设计方法和装置

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168384B2 (en) * 2007-10-12 2012-05-01 Guy's And St. Thomas' Nhs Foundation Trust Non-thiopurine methyltransferase related effects in 6-mercaptopurine therapy
CN105018583A (zh) * 2014-04-28 2015-11-04 博奥生物集团有限公司 用于检测华法林与氯吡格雷个体化用药相关基因的多态性的试剂盒及其应用
CN105734116A (zh) * 2014-12-08 2016-07-06 常州金麦格生物技术有限公司 多重核酸位点检测方法
CN105861678A (zh) * 2016-04-29 2016-08-17 广州市康立明生物科技有限责任公司 一种用于扩增低浓度突变靶序列的引物和探针的设计方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510979D0 (en) * 2005-05-28 2005-07-06 Kbiosciences Ltd Detection system for PCR assay
JP4580875B2 (ja) * 2006-01-20 2010-11-17 株式会社東芝 核酸検出法のためのプライマーの設計方法
JP2009125020A (ja) * 2007-11-26 2009-06-11 Canon Inc ハプロタイプの決定方法
EP2314680B1 (fr) * 2008-07-02 2014-10-01 ARKRAY, Inc. Procédé d'amplification d'une séquence d'acides nucléiques cible, procédé de détection de la mutation à l'aide du procédé, et réactifs en vue d'une utilisation dans les procédés
CN101619352B (zh) * 2009-01-23 2012-07-04 中南大学 一种基于等位基因特异性扩增的双探针基因突变检测方法及其专用芯片和试剂盒
CN101613698B (zh) * 2009-04-13 2011-06-15 厦门艾德生物医药科技有限公司 一种扩增低含量基因突变dna的引物设计方法及其应用
CN101608240B (zh) * 2009-04-13 2011-06-29 郑立谋 用于检测人类egfr基因突变的引物、探针及其使用方法
ES2642683T3 (es) * 2011-05-12 2017-11-17 Exact Sciences Corporation Aislamiento de ácidos nucleicos
CN102304581B (zh) * 2011-09-01 2013-10-30 广州好芝生物科技有限公司 用于检测kras基因突变的试剂盒及其检测方法
CN102776291B (zh) * 2012-08-16 2014-12-17 苏州工业园区为真生物医药科技有限公司 基于Taqman-ARMS技术检测基因突变分型的方法和试剂盒
CN103710431B (zh) * 2013-10-30 2017-04-19 常州市第三人民医院 一种检测基因突变的引物及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168384B2 (en) * 2007-10-12 2012-05-01 Guy's And St. Thomas' Nhs Foundation Trust Non-thiopurine methyltransferase related effects in 6-mercaptopurine therapy
CN105018583A (zh) * 2014-04-28 2015-11-04 博奥生物集团有限公司 用于检测华法林与氯吡格雷个体化用药相关基因的多态性的试剂盒及其应用
CN105734116A (zh) * 2014-12-08 2016-07-06 常州金麦格生物技术有限公司 多重核酸位点检测方法
CN105861678A (zh) * 2016-04-29 2016-08-17 广州市康立明生物科技有限责任公司 一种用于扩增低浓度突变靶序列的引物和探针的设计方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110551815A (zh) * 2018-05-30 2019-12-10 苏州云泰生物医药科技有限公司 检测人Ras基因突变的试剂盒及其使用方法
CN112481382A (zh) * 2020-12-09 2021-03-12 凯杰生物工程（深圳）有限公司 一种用于检测jak2基因的引物组合物和探针、试剂盒以及方法

Also Published As

Publication number Publication date
CN110951828A (zh) 2020-04-03
CN105861678B (zh) 2019-12-13
CN105861678A (zh) 2016-08-17

Similar Documents

Publication Publication Date Title
WO2017185766A1 (fr) Procédé de conception d'amorces et de sonde pour l'amplification d'une séquence cible mutante à faible concentration
JP6842450B2 (ja) 標的化ゲノム解析のための方法
CN107109485B (zh) 用于多重捕获反应的通用阻断寡聚物系统和改进的杂交捕获的方法
CN106795514B (zh) 泡状接头及其在核酸文库构建及测序中的应用
JP5945271B2 (ja) ニッキング酵素を用いたヘリカーゼ依存性等温増幅
TWI733038B (zh) 基因突變特異性擴增效率提高的ｄｎａ聚合酶
JP2013521776A5 (fr)
CN106755456B (zh) 用于线粒体全基因组检测的引物组合及试剂盒
US11155858B2 (en) Polynucleotide barcodes for long read sequencing
JP6804462B2 (ja) 指数関数の底が２より大きい核酸増幅
CN106636071B (zh) 一种恒温条件下合成核酸的方法
WO2019144582A1 (fr) Sonde et procédé destinés à une région cible de capture ciblée par le séquençage à haut débit utilisés pour la détection de mutations de gène ainsi que de types de fusion de gène connus et non connus
CN106460065A (zh) 用于基因组应用和治疗应用的核酸分子的克隆复制和扩增的系统和方法
AU2012223438A1 (en) Kit and method for sequencing a target DNA in a mixed population
EP3036343B1 (fr) Amplification hélicase-dépendante de molécules d'adn utilisant des analogues nucléotidiques
WO2019178346A1 (fr) Enrichissement d'acides nucléiques
CN107893109A (zh) 一种基于移除野生型序列的低丰度基因突变富集方法
JP2020536525A (ja) プローブ及びこれをハイスループットシーケンシングに適用するターゲット領域の濃縮方法
US20200216874A1 (en) Pcr primer pair and application thereof
JP2003534812A (ja) 制限プライマー伸長によるヌクレオチド配列変異の検出
CN105734679A (zh) 核酸靶序列捕获测序文库的制备方法
US10851408B2 (en) Methods and kits for detecting gene mutations
CN105793435A (zh) 多重探针
Shin et al. Multiplex ligase‐based genotyping methods combined with CE
US20130053253A1 (en) Region of Interest Extraction and Normalization Methods

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16900271

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 16900271

Country of ref document: EP

Kind code of ref document: A1